跳至主要内容
临床试验/NCT05667532
NCT05667532招募中不适用

The C-MERIT Screening Cohort: Contrast-enhanced Mammography for Breast Cancer Screening and Risk Assessment in Women With Dense Breasts

M.D. Anderson Cancer Center1 个研究点 分布在 1 个国家目标入组 1,000 人开始时间: 2022年12月5日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
招募中
入组人数
1,000
试验地点
1
主要终点
To identify female MDACC patients with dense breasts who undergo contrast-enhanced mammography

研究概览

简要总结

To learn whether a new imaging technology, Contrast-Enhanced Mammography (CEM), compared to standard mammography, can better detect breast cancers in women with dense breasts

详细描述

Primary Objectives:

  • To establish a cohort of 1,000 female MDACC patients with dense breasts who undergo screening contrast-enhanced mammography.
  • To establish a comprehensive integrated database of imaging, clinical data, health measurements, and questionnaire data including data from the companion protocol PA17-0584.

Secondary Objectives:

  • To perform within-subject comparison of the cancer detection rate between CEM and FFDM.
  • To perform within-subject comparison of the sensitivity, specificity, and recall rates of CEM compared to low-energy (LE) images (FFDM equivalent) and compared to a combination of LE and DBT images among women with dense breasts.
  • To evaluate the effect of the availability of prior imaging for comparison on the recall rates of CEM, FFDM and DBT.
  • In patients who undergo screening breast ultrasound as a standard of care, to evaluate the performance of screening ultrasound for breast cancer detection and compare it with other imaging modalities of CEM, LE images, and DBT.

Exploratory Objectives:

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Screening
盲法
None

入排标准

年龄范围
30 Years 至 75 Years(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Female patients 30-75 years of age with dense breasts (ACR BI-RADS categories C and D) who undergo routine yearly mammography at participating MDACC sites
  • Willingness to co-enroll or currently enrolled in PA17-0584
  • Willingness to participate in the study and ability to provide informed consent

排除标准

  • Self-reported new breast symptoms since last mammogram including nipple discharge, palpable mass, skin dimpling, or focal pain.
  • Current or recent (within the prior 6 months) history of pregnancy or breast feeding
  • Personal history of breast cancer (DCIS or invasive breast cancer)
  • Treatment of any other type of cancer within the past 5 years excluding in-situ cervical and non-melanoma skin cancer
  • Breast biopsy within 6 months
  • Breast surgery within 12 months
  • Breast MRI, MBI, or CEM performed within 24 months
  • Known allergy to iodine-containing contrast agents
  • History of anaphylactic reaction to any substance that required hospitalization or IV placement in a patient with no known prior uneventful exposure to iodine-based IV contrast
  • Renal insufficiency (as defined by UTMDACC policy 3.30- attachment 1 (appendix D)

研究组 & 干预措施

Contrast Enhanced Mammography

Experimental

干预措施: Contrast Enhanced Mammography (Diagnostic Test)

结局指标

主要结局

To identify female MDACC patients with dense breasts who undergo contrast-enhanced mammography

时间窗: through study completion; an average of 1 year.

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验